ABT Stock Chart & Stats
$1970.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1970.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,413.00 - $2,729.31
Previous CloseN/A
Volume0.00
Average Volume (3M)624.00
Market Cap
$3.06T
Enterprise Value$185.82K
Total Cash (Recent Filing)$5.60B
Total Debt (Recent Filing)$32.61B
Price to Earnings (P/E)32.8
Beta-0.20
Next Earnings
Oct 21, 2026EPS Estimate
24.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.11
Shares Outstanding1,730,383,300
10 Day Avg. Volume29
30 Day Avg. Volume624
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.20
Price to Sales (P/S)4.94
P/FCF Ratio29.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,131.62Price Target Upside8.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)93.3
Revenue Forecast (FY)$850.80B
Bulls Say, Bears Say
Bulls Say
Diversified Recurring Healthcare ModelAbbott’s exposure across devices, diagnostics, nutrition and pharmaceuticals reduces reliance on one product category or end market. Recurring sensor, reagent and nutrition purchases can support durable demand, while geographic breadth and product innovation provide multiple avenues for sustained growth over the next several quarters.
Strong Free Cash FlowRobust and growing free cash flow gives Abbott internal funding for research, product launches, acquisitions and shareholder returns. FCF also tracks earnings well at roughly 0.88 times net income, indicating that reported profitability is converting into cash and supporting financial resilience.
Broad Growth And Margin MomentumThe combination of reaffirmed sales growth, higher earnings guidance and 100 basis points of gross-margin expansion signals operating momentum across a diversified portfolio. Strength in devices, cancer diagnostics, nutrition and CGM provides several durable growth engines rather than dependence on a single product.
Bears Say
Debt Increased MateriallyThe sharp increase in debt reduces Abbott’s financial flexibility even though its equity base remains substantial. Higher leverage can constrain future investment or capital returns if operating conditions weaken, and it makes maintaining strong cash generation more important for funding obligations and strategic initiatives.
Recent Margin CompressionMargin normalization is a fundamental concern because weaker profit conversion can limit earnings growth even while revenue rises. If the lower margin profile persists, Abbott may have less capacity to absorb cost pressure, fund innovation and expand returns, particularly alongside its higher debt burden.
Ongoing Formula Litigation ExposureThe settlement reduces uncertainty for some claims but does not resolve Abbott’s broader formula litigation exposure. Remaining lawsuits could continue to create financial costs, management distraction and reputational pressure, making the issue a durable overhang over the coming quarters despite the partial resolution.
Abbott Laboratories News
ABT FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was $1413.00 and its highest was $2729.31 in the past 12 months.
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is $3.06T.
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Oct 21, 2026 which is in 35 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Jul 16, 2026. The company reported $22.192 earnings per share for the quarter, beating the consensus estimate of $21.633 by $0.559.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories does not currently pay dividends.
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is 24.04.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,730,383,300 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $22.192 in its last earnings report, beating expectations of $21.633. Following the earnings report the stock price went up 11.108%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Currently, no hedge funds are holding shares in MX:ABT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abbott Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2,131.62 (8.20% Upside)
$2,131.62 (8.20% Upside)
Blogger Sentiment
Bullish
MX:ABT Sentiment 83%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth $792.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.51%
12-Months-Change
Fundamentals
Return on Equity
2.42%
Trailing 12-Months
Asset Growth
30.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
ABT Company Deck
ABT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall, the call conveyed constructive momentum across Abbott’s diversified portfolio with multiple product and regulatory milestones, gross margin expansion, and raised EPS guidance. Key growth engines — diagnostics (notably cancer testing), nutrition recovery, devices (EP, rhythm management, heart failure) and diabetes/CGM — provide visibility to second-half acceleration. Offsetting risks include a soft respiratory season hurting rapid/molecular diagnostics, China VBP headwinds, structural heart US commercial execution needs, and uncertainty/timing around reimbursement and regulatory approvals for some high-impact products (e.g., CGM reimbursement expansion, Libre Duo FDA clearance). On balance, highlights notably outweigh the lowlights, with achievable near-term drivers and a clear pipeline cadence underpinning positive momentum.View all MX:ABT earnings summariesABT Net sales Breakdown
12.49% Established Pharmaceutical Products
19.06% Nutritional Products
20.16% Diagnostic Products
48.25% Medical Devices
0.04% Other

ABT Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$2,131.62
▲(8.20% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Boston Scientific
―
Dexcom
―
Edwards Lifesciences
―
Medtronic
―
GE Healthcare Technologies Inc
―









